The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnetic Resonance Imaging and Acute Low Back Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06022484
Recruitment Status : Completed
First Posted : September 5, 2023
Last Update Posted : February 6, 2024
Sponsor:
Information provided by (Responsible Party):
International Institute of Behavioral Medicines

Tracking Information
First Submitted Date August 21, 2023
First Posted Date September 5, 2023
Last Update Posted Date February 6, 2024
Actual Study Start Date September 15, 2023
Actual Primary Completion Date December 31, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 1, 2023)
Two questions on limit of tolerance [ Time Frame: Up to the first day ]
Design of questions which investigates the limit of tolerance of requesting and prescribing a MRI; score is expressed as "number of days" (neither min nor max values are stated a priori).
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: September 1, 2023)
  • NRS [ Time Frame: Up to the first day ]
    pain intensity Numerical Rating Scale; score 0-10 with higher estimates indicating higher levels of pain intensity
  • PCS [ Time Frame: Up to the first day ]
    Pain Catastrophizing Scale; score 0-52 with higher estimates indicating higher levels of catastrophizing.
  • ZUNG [ Time Frame: Up to the first day ]
    Zung Self-Rating Anxiety Scale; score 20-80 with higher estimates indicating higher levels of anxiety
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Magnetic Resonance Imaging and Acute Low Back Pain
Official Title How Many Days Will You Delay Before a MRI When You Have Low Back Pain?
Brief Summary This is a behavioral observational study aimed at understanding the limit of tolerance (in days) of ideally performing a Magnetic Resonance Imaging (MRI) by people with acute low back pain. It consists of a short self-administered questionnaire. Relationships between low back pain intensity, maladaptive thoughts and awaited days before ideally requesting a MRI will be evaluated.
Detailed Description

This is a behavioral observational study aimed at understanding the limit of tolerance (in days) of ideally performing a Magnetic Resonance Imaging (MRI) by people with acute low back pain (LBP) and by general practitioners (GP).

Literature pointed out that LBP is a common occurrence in people, with high rates of self-resolution in the absence of red flags (i.e. possible indicators of serious spinal pathology).

In Italy there is an over-prescription of MRI despite international guidelines go the opposite way.

The study consists of a short self-administered questionnaire which will be given to people and GP to complete. In more details, the survey is made of 3 questions collecting information on the limit of tolerance (in days) before requesting (people) and prescribing (GP) a MRI for the lumbar tract of the spinal column.

Further, participants will have to complete a self-administered pain intensity numerical rating scale, along with catastrophizing and anxiety self-administered questionnaires.

Descriptive statistics will be presented by taking into account the socio-demographic characteristics of the sample being investigated. Statistical correlations between participants' answers and the scores from the questionnaires will be also evaluated.

This study investigates the relationships among acute low back pain, the intention of persons/GP to request/prescribe a MRI despite the absence of red flags, mood disorders and maladaptive thoughts.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population

Adult people with acute low back pain (i.e., a pain lasting no more than 6 weeks).

General practitioners who are involved in the managment of people with acute low back pain.

Condition Acute Low Back Pain
Intervention Other: The present study does not contain any intervention
The present study does not contain any intervention
Study Groups/Cohorts
  • People with acute low back pain
    No intervention.
    Intervention: Other: The present study does not contain any intervention
  • General practitioners who treat people with acute low back pain
    No intervention.
    Intervention: Other: The present study does not contain any intervention
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: September 1, 2023)
100
Original Estimated Enrollment Same as current
Actual Study Completion Date December 31, 2023
Actual Primary Completion Date December 31, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Having acute low back pain (i.e., a pain lasting no more than 6 weeks)
  • Adult age
  • Ability to understand the Italian language

Exclusion Criteria:

  • Mental deficits
  • Refuse to adhere to the study.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Italy
Removed Location Countries  
 
Administrative Information
NCT Number NCT06022484
Other Study ID Numbers 2023-005
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Current Responsible Party International Institute of Behavioral Medicines
Original Responsible Party Same as current
Current Study Sponsor International Institute of Behavioral Medicines
Original Study Sponsor Same as current
Collaborators Not Provided
Investigators Not Provided
PRS Account International Institute of Behavioral Medicines
Verification Date February 2024